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OBJECTIVES: The aim of this analysis was to project the long-
term clinical and economic outcomes associated with therapy
conversion from human premix insulin to Biphasic Insulin
Aspart 30 (BIAsp 30) in type 2 diabetes patients in a Polish
setting. METHODS: A previously published and validated com-
puter simulation model for diabetes was used to make long-term
projections of clinical and cost outcomes based on patient char-
acteristics and treatment effects from a sub-analysis of the
PRESENT study (1219 patients). The study analyzed the impact
of converting patients receiving human premix insulin (with or
without conventional oral medication) to treatment with BIAsp
30 whilst maintaining existing oral therapy. Probabilities of
complications were derived from landmark clinical and epide-
miological studies and the costs of treating complications in
Poland were retrieved from published sources. Total direct costs
(complications + treatment costs) were projected over patient
lifetimes with both costs and clinical outcomes discounted at
5% per annum. RESULTS: Improved glycemic control (HbA1c
reduction of 1.82%) and decreased hypoglycemic events asso-
ciated with BIAsp 30 were projected to lead to fewer diabetes-
related complications and an increase in quality-adjusted
life expectancy of 0.280 quality-adjusted life years (QALYs)
(3.338  0.075 versus 3.058  0.072 QALYs). The re-
duction in predicted diabetes-related complications resulted in a
net saving in direct medical costs of PLN 7,790 (PLN
28,746  1,097 versus 36,536  1,379). CONCLUSION: This
modeling study indicated that the increased cost of therapy for
BIAsp 30 versus human premix insulin will be offset by reduc-
tions in the cost of diabetes-related complications leading to a
net saving in direct costs. Moreover, BIAsp 30 was associated
with improved life expectancy and quality-adjusted life expect-
ancy, making it a dominant treatment option compared to
human premix insulin.
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OBJECTIVES: Diabetic nephropathy is the leading cause of end-
stage renal disease (ESRD), which is related to substantial clinical
and economic burden. The purpose of this study was to compare
the efﬁcacy and costs of angiotensin converting enzyme inhibitors
(ACEi) and angiotensin receptor blockers (ARBs) in patients
with diabetic nephropathy. METHODS: We performed a cost-
effectiveness analysis based on numbers needed to treat (NNT).
Clinical inputs were derived from a meta-analysis of randomized
controlled trials investigating the effect of ACEi and ARBs on the
incidence of ESRD in patients with diabetic nephropathy. Analy-
sis was by a random-effects model, and results were expressed as
relative risks (RR) and NNT. All costs were calculated from a
public insurance system perspective, in 2006 Euros. Future
costs and clinical beneﬁts were discounted at 3%. RESULTS:
Compared with placebo or no treatment, ARBs signiﬁcantly
reduced the incidence of ESRD (RR 0.78; 95% CI 0.67 to 0.91;
P = 0.001) but not ACEi (RR 0.70; 95% CI 0.47 to 1.06;
P = 0.09). The weighted mean lifetime direct cost of ESRD
from the perspective of the insurance system was estimated at
146,039 Euros in Greece for a 65 year-old diabetic patient
(mean age of the studies’ population). The cost to prevent one
patient to develop ESRD was 23,678 Euros (95% CI 14,510 to
63,763 Euros; P < 0.01) for patients receiving ARBs and
141,187 Euros (95% CI 29,412 Euros to inﬁnity; P = 0.13) for
patients receiving ACE inhibitors. CONCLUSION: In diabetic
nephropathy, ARBs is the most cost-effective drug class com-
paring with ACEi, placebo or no treatment. Treating patients
with diabetic nephropathy using ARBs reduces the incidence of
ESRD and can result in substantial cost savings for the public
insurance system.
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OBJECTIVES: This study assessed the cost-effectiveness of type
1 diabetic patients treated with insulin detemir based basal-bolus
therapy versus neutral protamine Hagedorn (NPH) insulin based
basal-bolus therapy in a Belgian setting using results obtained
from a meta-analysis of three clinical trials. The meta-analysis
demonstrated an improvement for detemir over NPH in
HbA1c (0.13% points lower), lower body mass index (BMI)
(0.21 kg.m-2) and a 4% decrease in hypoglycemic events, when
used in combination with either insulin aspart or human soluble
insulin. METHODS: A published and validated computer simu-
lation model for diabetes (the CORE Diabetes Model) was used
to project short-term results obtained from the ﬁxed-effects meta-
analysis to estimate long-term clinical and cost outcomes for
detemir based basal-bolus therapy versus NPH based basal-bolus
therapy using Belgian speciﬁc patient characteristics, mortality
rates and costs of treating complications derived from published
sources. Probabilities of complications were derived from land-
mark clinical and epidemiological studies. Total direct costs
(complications + treatment costs) for each arm were projected
over patient lifetimes. Future costs and clinical beneﬁts were
discounted at respectively 3% and 1.5% per annum in line with
published guidance. RESULTS: Short-term therapy beneﬁts asso-
ciated (improved glycemic control, decreased hypoglycemic
events and lower BMI) with detemir based basal-bolus therapy
led to fewer diabetes-related complications, and a resulting
increase in quality-adjusted life expectancy of 0.173 quality-
adjusted life years (QALYs) (7.296  0.111 versus 7.123 
0.115 QALYs). Higher therapy costs for detemir versus NPH
resulted in an increased lifetime costs/patient of €5,075
(€86,602  1730 versus €81,527) and a resultant incremental
cost-effectiveness ratio of €29,288 per QALY gained. CONCLU-
SION: The clinical beneﬁts demonstrated in the meta-analysis for
detemir over NPH in basal-bolus therapy predict long-term
outcome improvements which reduce diabetes related complica-
tions, increased patient quality of life and result in an incremental
cost-effectiveness ratio which represents good value for money
in Belgium.
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